An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03917719 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Stopped The Phase 3 PolarisDMD trial did not meet the primary endpoint. As a result, activities related to the development of edasalonexent have stopped including the CAT-1004-302 Open-Label Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: Edasalonexent

Sponsor

Catabasis Pharmaceuticals